» Articles » PMID: 38094893

TCM and Related Active Compounds in the Treatment of Gout: the Regulation of Signaling Pathway and Urate Transporter

Overview
Journal Front Pharmacol
Date 2023 Dec 14
PMID 38094893
Authors
Affiliations
Soon will be listed here.
Abstract

Gout represents a metabolic ailment resulting from the accumulation of monosodium urate crystals within joints, causing both inflammation and, harm to tissues. The primary contributor to gout's emergence is an elevated presence of serum urate, which is under the regulation of kidney and, gut urate transporters. Mitigating this risk factor is crucial for averting gout's onset. Several treatments rooted in TCM and related active compounds have demonstrated efficacy in managing gout, skillfully regulating serum uric acid (UA) levels and curbing inflammation's progression. This analysis compiles key foundational research concerning the molecular signaling pathways and UA transporters linked to gout, under the regulation of TCM. The focus includes individual botanical drug, active compounds, and TCM formulations, which have been consolidated and examined in this overview. The primary keywords chosen were "gout, hyperuricemia, gouty arthritis, traditional Chinese medicine, Chinese botanical drug, medicinal botanical drug, and natural plant". Various relevant literature published within the last 5 years were gathered from electronic databases, including PubMed, Web of Science, CNKI, and others. The findings revealed that TCM has the capacity to modulate various signaling pathways, including MAPK, NF-κB, PI3K/Akt, NLRP3 and JAK/STAT. Additionally, it impacts UA transporters like URAT1, GLUT9, ABCG2, as well as OATs and OCTs, thereby contributing to gout treatment. TCM helps maintain a balanced inflammatory interaction and facilitates UA excretion. This study enhances our understanding of TCM's anti-gout mechanisms and introduces novel perspectives for establishing the clinical significance and future prospects of TCM-based gout treatment.

Citing Articles

A targeted proteomics screen reveals serum and synovial fluid proteomic signature in patients with gout.

Huang Z, Zhong X, Zhang Y, Li X, Liu M, Huang Y Front Immunol. 2024; 15:1468810.

PMID: 39611154 PMC: 11602490. DOI: 10.3389/fimmu.2024.1468810.


Regulating Lipid Metabolism in Gout: A New Perspective with Therapeutic Potential.

Zhang X, Liu J Int J Gen Med. 2024; 17:5203-5217.

PMID: 39554874 PMC: 11568860. DOI: 10.2147/IJGM.S499413.


Investigating the mechanisms of resveratrol in the treatment of gouty arthritis through the integration of network pharmacology and metabolics.

Xu X, Yu D, Wang Y, Jiang X, Lu F, Liu S Front Endocrinol (Lausanne). 2024; 15:1438405.

PMID: 39534253 PMC: 11555470. DOI: 10.3389/fendo.2024.1438405.

References
1.
de Almeida L, Devi S, Indramohan M, Huang Q, Ratsimandresy R, Pope R . POP1 inhibits MSU-induced inflammasome activation and ameliorates gout. Front Immunol. 2022; 13:912069. PMC: 9550078. DOI: 10.3389/fimmu.2022.912069. View

2.
Lin S, Meng J, Li F, Yu H, Lin D, Lin S . polysaccharide peptide alleviates hyperuricemia by regulating adenosine deaminase and urate transporters. Food Funct. 2022; 13(24):12619-12631. DOI: 10.1039/d2fo02431d. View

3.
Meng J, Tian J, Zhao Y, Li C, Yi Y, Zhang Y . Ameliorative effect of cheqianzi decoction on hyperuricemia and kidney injury and underlying mechanism in rats. Heliyon. 2023; 9(4):e15333. PMC: 10130219. DOI: 10.1016/j.heliyon.2023.e15333. View

4.
Zhang M, Sun K, Guo X, Chen Y, Feng C, Chen J . The antihyperuricemia activity of Astragali Radix through regulating the expression of uric acid transporters via PI3K/Akt signalling pathway. J Ethnopharmacol. 2023; 317:116770. DOI: 10.1016/j.jep.2023.116770. View

5.
Wu M, Ma Y, Chen X, Liang N, Qu S, Chen H . Hyperuricemia causes kidney damage by promoting autophagy and NLRP3-mediated inflammation in rats with urate oxidase deficiency. Dis Model Mech. 2021; 14(3). PMC: 8015218. DOI: 10.1242/dmm.048041. View